The ENACT Trial: A Randomized, Double-blind, Placebo-controlled Adjunctive Treatment Trial to Evaluate the Efficacy and Safety of ENX-101 in Patients With Focal (Partial Onset) Seizures
Latest Information Update: 10 Jul 2023
Price :
$35 *
At a glance
- Drugs ENX-101 (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Acronyms ENACT
- Sponsors Engrail Therapeutics
- 03 Jul 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Jul 2022 Status changed from planning to not yet recruiting.
- 13 Jun 2022 New trial record